Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
Want to see MIST full AI Analyst Report?
Top Page
Milestone Pharmaceuticals
(NASDAQ:MIST)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.00
▼(-4.76% Downside)
Action:ReiteratedDate:04/10/26
Overall score is held back primarily by weak financial performance (large losses, significant cash burn, and elevated leverage). Offsetting factors include constructive price trends and meaningful positive corporate developments (U.S. product launch and $75M non-dilutive financing), while valuation remains challenged due to ongoing losses and no dividend support.
Positive Factors
U.S. product launch
Regulatory approval and a U.S. retail launch create a durable commercial foundation: enables revenue generation, builds sales and distribution capabilities, and supports physician/payer engagement. Over 2-6 months this underpins scaling potential if adoption grows.
Negative Factors
Low revenue base
Modest trailing revenues versus substantial operating costs indicate the business has not reached commercial scale. Persistent low sales limit self-sustaining growth, require continued external funding, and make achieving profitable margins a multi-period challenge.
Read all positive and negative factors
Positive Factors
Negative Factors
U.S. product launch
Regulatory approval and a U.S. retail launch create a durable commercial foundation: enables revenue generation, builds sales and distribution capabilities, and supports physician/payer engagement. Over 2-6 months this underpins scaling potential if adoption grows.
Read all positive factors
Milestone Pharmaceuticals (MIST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$220.04M
Dividend YieldN/A
Average Volume (3M)2.71M
Price to Earnings (P/E)―
Beta (1Y)2.69
Revenue GrowthN/A
EPS Growth-10.20%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding117,667,274
10 Day Avg. Volume3,680,992
30 Day Avg. Volume2,712,159
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)4.06
Price to Sales (P/S)109.60
P/FCF Ratio-3.43
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue94.40
Enterprise Value/Gross Profit98.15
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$7.33Price Target Upside249.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$45.77M
Milestone Pharmaceuticals Business Overview & Revenue Model
Company Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the t...
How the Company Makes Money
null...
Milestone Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.55M | 0.00 | 1.00M | 5.00M | 15.00M |
| Gross Profit | 1.43M | 0.00 | 1.00M | 5.00M | 15.00M |
| EBITDA | -62.14M | -37.83M | -57.04M | -58.30M | -42.98M |
| Net Income | -63.06M | -41.52M | -59.69M | -58.39M | -42.85M |
Balance Sheet | |||||
| Total Assets | 113.56M | 75.50M | 75.23M | 74.48M | 119.85M |
| Cash, Cash Equivalents and Short-Term Investments | 105.96M | 69.69M | 66.00M | 64.58M | 114.14M |
| Total Debt | 58.38M | 54.80M | 51.77M | 2.49M | 698.00K |
| Total Liabilities | 71.79M | 62.35M | 58.45M | 8.13M | 7.25M |
| Stockholders Equity | 41.77M | 13.15M | 16.77M | 66.35M | 112.60M |
Cash Flow | |||||
| Free Cash Flow | -49.34M | -28.88M | -46.54M | -52.74M | -33.22M |
| Operating Cash Flow | -49.04M | -28.85M | -46.42M | -52.47M | -33.22M |
| Investing Cash Flow | 11.25M | 8.28M | 4.76M | -57.12M | 70.00M |
| Financing Cash Flow | 85.53M | 32.12M | 47.79M | 3.09M | 5.05M |
Milestone Pharmaceuticals Technical Analysis
Positive
2.10
Price Trends
1.66
Positive
1.93
Positive
1.89
Positive
Market Momentum
0.15
Negative
66.18
Neutral
81.34
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MIST, the sentiment is Positive. The current price of 2.1 is above the 20-day moving average (MA) of 1.57, above the 50-day MA of 1.66, and above the 200-day MA of 1.89, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 66.18 is Neutral, neither overbought nor oversold. The STOCH value of 81.34 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MIST.
Milestone Pharmaceuticals Risk Analysis
Milestone Pharmaceuticals disclosed 70 risk factors in its most recent earnings report. Milestone Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Milestone Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $182.69M | -1.38 | -65.76% | ― | ― | -63.15% | |
54 Neutral | $796.72M | -8.12 | -48.16% | ― | ― | 1.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $220.04M | -2.69 | -656.82% | ― | ― | -10.20% | |
50 Neutral | $201.08M | -3.95 | -977.67% | ― | ― | 42.43% | |
47 Neutral | $366.25M | -3.11 | -77.91% | ― | -86.62% | 95.62% | |
40 Underperform | $73.30M | -2.15 | 13.30% | ― | ― | ― |
* Healthcare Sector Average
MIST
Milestone Pharmaceuticals
1.87
0.54
40.60%
CRBP
Corbus Pharmaceuticals
10.30
2.88
38.81%
MCRB
Seres Therapeutics
7.61
-1.62
-17.55%
AVTX
Avalo Therapeutics
13.71
8.69
173.11%
ELTX
Elicio Therapeutics
10.75
5.34
98.71%
ANRO
Alto Neuroscience, Inc.
24.94
22.59
961.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.